ANCA-Positive Patients: The Influence of PR3 and MPO Antibodies on Survival Rate and The Association with Clinical and Laboratory Characteristics

J.C Drooger*, A Dees, A.J.G Swaak
Departments of Internal Medicine and Rheumatology, Ikazia Hospital, Postbus 5009, 3008 AA, Rotterdam, The Netherlands

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 2518
Abstract HTML Views: 2020
PDF Downloads: 862
Total Views/Downloads: 5406
Unique Statistics:

Full-Text HTML Views: 1322
Abstract HTML Views: 1288
PDF Downloads: 608
Total Views/Downloads: 3224

Creative Commons License
© Drooger et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Departments of Internal Medicine and Rheumatology, Ikazia Hospital, Postbus 5009, 3008 AA, Rotterdam, The Netherlands; Tel: +31 10 2975000; Fax: +31 10 2975400; E-mail:



To compare the survival rate, and the clinical and laboratory characteristics in patients, characterized by the presence of certain anti-neutrophil cytoplasmic auto-antibodies (ANCAs).


In a retrospective observational study, we analyzed the data of all patients with a positive ANCA test between 1995 and 2005 at our hospital. Based on serology patients were divided in three subgroups (ANCA-Proteinase 3 (PR3), ANCA-Myeloperoxidase (MPO) and atypical ANCA), irrespective of the diagnosis. Patient survival was compared by Kaplan Meier survival analysis. Differences in clinical and laboratory characteristics between the groups of specific ANCAs were determined.


Fifty-four ANCA-positive patients were analyzed. Eighteen of these patients were ANCA-PR3-positive, 17 were ANCA-MPO-positive and 19 had a atypical ANCA. A random control group was created of matched ANCA negative patients. Average follow-up time was 52 months. The calculated five year survival rate in respectively the ANCA-PR3- positive group, the ANCA-MPO-positive group, the atypical ANCA group and the ANCA-negative group was 45%, 81%, 90% and 100%. (P = 0.012, Wilcoxon test). A higher mean leukocyte count, a higher mean erythrocyte sedimentation rate and more fever was observed in the ANCA-PR3-positive group compared to the ANCA-MPO-positive group.


A remarkable lower survival rate was observed in ANCA-PR3-positive patients compared to ANCA-MPO-positive patients. We also demonstrated that patients characterized by the presence of a defined ANCA differ in clinical and laboratory characteristics.

Keywords: ANCA, anti-myeloperoxidase (MPO), anti-proteinase3 (PR3), survival, prognostic value..